

Table of Contents

Preface to the second edition	V
Abbreviations	XVII
A. Life Science Matter	1
A.I. Summary of historical development	1
A.II. Definition of life science matter	2
B. Legal Provisions	3
B.I. European Patent Convention (EPC)	3
B.II. EU Law	5
B.II.1. EU Biotech Directive and its Implementation into the EPC	5
B.II.2. EU Regulations Concerning the Creation of a Supplementary Protection Certificate (SPC) for Medicinal Products (MSPC), Pediatric Extension of Duration for Medicinal Products (PE) and Plant Protection Products (PSPC)	5
B.II.3. Council Regulation on Community Plant Variety Rights (CPVR)	6
B.II.4. EU Bolar Directive	6
C. General Aspects on Protection	7
C.I. Protection under the EPC	7
C.I.1. Non-patentable matter	7
C.I.1.a. Discoveries	7
C.I.2. Exceptions to patentability	9
C.I.2.a. Inventions contrary to "ordre public" or morality	9
C.I.2.b. Plant and animal varieties	14
C.I.2.b.a. Plant Varieties	14
C.I.2.b.b. Animal Varieties	15
C.I.2.c. Essentially biological processes for the production of plants or animals	16
C.I.2.d. Methods for treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body	20
C.I.3. Requirements for grant	27
C.I.3.a. Novelty, inventive step and industrial application	27
C.I.3.a.a. Naturally occurring products	27
C.I.3.a.b. Products for use in methods for treatment of the human or animal body by surgery, therapy or diagnostic methods practiced on the human or animal body	28
C.I.3.a.c. Processes of analogy	28
C.I.3.b. Sufficiency of disclosure	29
C.I.3.b.a. Nucleotide and amino acid sequences	37
C.I.3.b.b. Microorganisms	38

C.I.3.c.	Priority	40
C.I.3.d.	Person skilled in the art	43
C.I.3.e.	Claims	45
C.I.3.e.a.	Claim categories	46
C.I.3.e.b.	Clarity of claims	47
C.I.3.e.c.	Support of claims by description	49
C.I.3.e.d.	Claims for medicinal products	51
C.I.3.e.e.	Unity of invention	52
C.I.3.f.	Description	54
C.I.3.f.a.	Selection inventions	54
C.I.3.f.b.	Divisional applications	56
C.I.3.f.c.	Quality and filing of data	58
C.II.	Protection under the EU Regulations	61
C.II.1.	SPCs	61
C.II.2.	Protecting plants under the CPVR	66
C.II.2.a.	General background	66
C.II.2.b.	Formal and substantive requirements for grant of a new plant variety right; legal recourse	67
C.II.2.c.	Form and duration of the Community Plant Variety Right	68
D.	Protectable Matter in the Life Sciences	71
D.I.	Small Molecules and Polymers	71
D.I.1.	Product claims for low molecular products and polymers	73
D.I.2.	Process claims for low molecular products and polymers	77
D.I.3.	Use claims/purpose-limited product claims for low molecular products and polymers	78
D.II.	Nucleic acids	79
D.II.1.	Introduction	79
D.II.2.	Protecting nucleic acids under the EPC	80
D.II.2.a.	Discoveries	80
D.II.2.b.	Morality and "ordre public"	81
D.II.2.c.	Methods of treatment	82
D.II.2.d.	Novelty	82
D.II.2.e.	Inventive Step	87
D.II.2.f.	Industrial application	96
D.II.2.g.	Sufficiency of disclosure	97
D.II.2.h.	Clarity and support of claims	106
D.II.2.i.	Product claims for nucleic acids	109
D.II.2.i.a.	Product claims characterizing a nucleic acid by functional terms	111
D.II.2.i.b.	Product claims characterizing a nucleic acid by part or all of the amino acid sequence of the encoded protein	117
D.II.2.i.c.	Product claims characterizing a nucleic acid by part or all of the nucleic acid sequence itself	119
D.II.2.i.d.	Product claims characterizing a nucleic acid by parameters	122
D.II.2.i.e.	Product claims characterizing a nucleic acid by reference to a deposited microorganism or deposited DNA	124
D.II.2.i.f.	Product claims characterizing a nucleic acid by a process for its preparation	125
D.II.2.i.g.	Product claims comprising nucleic acids as essential elements	127

D.II.2.i.h.	Product claims for certain types of nucleic acids and methods of using same	129
D.II.2.j.	Process claims for nucleic acids	131
D.II.2.j.a.	Process claims involving genetic engineering or synthesis	132
D.II.2.j.b.	Process claims involving isolation from a nucleic acid source	132
D.II.2.k.	Use claims/purpose-limited product claims for nucleic acids	135
D.III.	Proteins	137
D.III.1.	Introduction	137
D.III.2.	Protecting proteins under the EPC	137
D.III.2.a.	Discoveries	138
D.III.2.b.	Morality and "ordre public"	139
D.III.2.c.	Methods of treatment	139
D.III.2.d.	Novelty	139
D.III.2.e.	Inventive step	145
D.III.2.f.	Industrial application	154
D.III.2.g.	Sufficiency of disclosure	156
D.III.2.h.	Clarity and support of claims	161
D.III.2.i.	Product claims for proteins	166
D.III.2.i.a.	Product claims characterizing a protein by functional terms	166
D.III.2.i.b.	Product claims characterizing a protein by parameters	168
D.III.2.i.c.	Product claims characterizing a protein by the coding capacity of a certain DNA	171
D.III.2.i.d.	Product claims characterizing a protein by its structure	172
D.III.2.i.e.	Product claims characterizing a protein by a process for its preparation	175
D.III.2.i.f.	Product claims comprising proteins as essential elements	177
D.III.2.j.	Process claims for proteins	179
D.III.2.j.a.	Process claims involving isolation from a natural environment	179
D.III.2.j.b.	Process claims involving synthesis by recombinant host cells	180
D.III.2.k.	Use claims/purpose-limited product claims for proteins	183
D.IV.	Antibodies	184
D.IV.1.	Introduction	184
D.IV.2.	Protecting antibodies under the EPC	184
D.IV.2.a.	Discoveries	185
D.IV.2.b.	Morality and "ordre public"	186
D.IV.2.c.	Methods of treatment	186
D.IV.2.d.	Novelty	186
D.IV.2.e.	Inventive Step	189
D.IV.2.f.	Industrial application	195
D.IV.2.g.	Sufficiency of disclosure	195
D.IV.2.h.	Clarity and support of claims	200
D.IV.2.i.	Product claims for antibodies	203
D.IV.2.i.a.	Product claims characterizing an antibody by functional terms	205
D.IV.2.i.b.	Product claims characterizing an antibody by parameters	209
D.IV.2.i.c.	Product claims characterizing an antibody by the coding sequence of a certain DNA	210
D.IV.2.i.d.	Product claims characterizing an antibody by its structure	210
D.IV.2.i.e.	Product claims characterizing an antibody by a process for its preparation	213
D.IV.2.i.f.	Product claims comprising antibodies as essential elements	215
D.IV.2.j.	Process claims for antibodies	216
D.IV.2.j.a.	Process claims involving isolation from a natural environment	216

D.IV.2.j.b.	Process claims involving synthesis by a recombinant host cell	216
D.IV.2.j.c.	Process claims involving secretion by hybridomas	217
D.IV.2.k.	Use claims/purpose-limited product claims for antibodies	218
D.V.	Microorganisms	219
D.V.1.	Introduction	219
D.V.2.	Protecting microorganisms under the EPC	219
D.V.2.a.	Discoveries	220
D.V.2.b.	Morality and "ordre public"	221
D.V.2.c.	Methods of treatment	221
D.V.2.d.	Novelty	221
D.V.2.e.	Inventive step	222
D.V.2.e.a.	Inventive step in cases where the microorganism is a hybridoma	222
D.V.2.e.b.	Inventive step in cases where the microorganism is not a hybridoma	224
D.V.2.f.	Sufficiency of disclosure	226
D.V.2.f.a.	Necessity of a deposit	226
D.V.2.f.b.	Other requirements for sufficiency of disclosure	229
D.V.2.f.c.	Reproducibility with certainty	233
D.V.2.g.	Clarity and support of claims	235
D.V.2.g.a.	Functional features in claims	235
D.V.2.g.b.	Clarity and the view of the skilled person	236
D.V.2.h.	Product claims for microorganisms	238
D.V.2.h.a.	Product claims characterizing a microorganism by functional terms	239
D.V.2.h.b.	Product claims characterizing a microorganism by a certain DNA or plasmid	240
D.V.2.h.c.	Product claims characterizing a microorganism by parameters	242
D.V.2.h.d.	Product claims characterizing a microorganism by a process for its preparation	243
D.V.2.h.e.	Product claims characterizing a microorganism by its deposit number	244
D.V.2.i.	Process claims for microorganisms	245
D.V.2.i.a.	Process claims for preparing a microorganism	245
D.V.2.i.b.	Process claims involving use of a microorganism	248
D.V.2.j.	Use claims/purpose-limited product claims for microorganisms	251
D.VI.	Plants	252
D.VI.1.	Introduction	252
D.VI.2.	Protecting plants under the EPC	253
D.VI.2.a.	Morality and "ordre public"	253
D.VI.2.b.	Plant varieties and essentially biological processes	253
D.VI.2.b.a.	Plant varieties	254
D.VI.2.b.b.	Essentially biological processes	256
D.VI.2.c.	Sufficiency of disclosure	260
D.VI.2.d.	Clarity and support of claims	264
D.VI.2.e.	Natural plants	266
D.VI.2.e.a.	Product claims for natural plants	266
D.VI.2.e.b.	Process claims for natural plants	270
D.VI.2.e.c.	Use claims/purpose-limited product claims for natural plants	273
D.VI.2.f.	Hybrid plants	274
D.VI.2.f.a.	Product claims for hybrid plants	274
D.VI.2.f.b.	Process claims for hybrid plants	276
D.VI.2.f.c.	Use claims/purpose-limited product claims for hybrid plants	278

D.VI.2.g.	Transgenic plants	278
D.VI.2.g.a.	Product claims for transgenic plants	278
D.VI.2.g.b.	Process claims for transgenic plants	284
D.VI.2.g.c.	Use claims/purpose-limited product claims for transgenic plants	288
D.VI.2.h.	Parts of plants	288
D.VI.2.h.a.	Highly differentiated parts of plants	290
D.VI.2.h.a.a.	Product claims for highly differentiated parts of plants	290
D.VI.2.h.a.b.	Process claims for highly differentiated parts of plants	292
D.VI.2.h.a.c.	Use claims/purpose-limited product claims for highly differentiated parts of plants	294
D.VI.2.h.b.	Undifferentiated or poorly differentiated parts of plants	295
D.VI.2.h.b.a.	Product claims for undifferentiated or poorly differentiated parts of plants	295
D.VI.2.h.b.b.	Process claims for undifferentiated or poorly differentiated parts of plants	298
D.VI.2.h.b.c.	Use claims/purpose-limited product claims for undifferentiated or poorly differentiated parts of plants	299
D.VI.2.i.	Summary	299
D.VII.	Animals	300
D.VII.1.	Introduction	300
D.VII.2.	Protecting animals under the EPC	301
D.VII.2.a.	Sufficiency of disclosure	302
D.VII.2.b.	Natural animals	303
D.VII.2.b.a.	Product claims for natural animals	303
D.VII.2.b.b.	Process claims for natural animals	305
D.VII.2.b.c.	Use claims/purpose-limited product claims for natural animals	309
D.VII.2.c.	Transgenic animals	311
D.VII.2.c.a.	Product claims for transgenic animals	311
D.VII.2.c.a.a.	Morality and "ordre public"	311
D.VII.2.c.a.b.	Animal varieties and essentially biological processes	315
D.VII.2.c.b.	Process claims for transgenic animals	318
D.VII.2.c.c.	Use claims/purpose-limited product claims for transgenic animals	321
D.VII.2.d.	Parts of animals	322
D.VII.2.d.a.	Product claims for parts of animals	322
D.VII.2.d.b.	Process claims for parts of animals	324
D.VII.2.d.c.	Use claims/purpose-limited product claims for parts of animals	327
D.VII.2.e.	Summary	328
D.VIII.	Human Body	329
D.VIII.1.	Introduction	329
D.VIII.2.	Protecting the human body under the EPC	329
D.VIII.2.a.	Human body	330
D.VIII.2.a.a.	Product claims for the human body	330
D.VIII.2.a.b.	Process claims for the human body	330
D.VIII.2.a.c.	Use claims/purpose-limited product claims for the human body	332
D.VIII.2.b.	Parts of the human body	333
D.VIII.2.b.a.	Product claims for parts of the human body	333
D.VIII.2.b.b.	Process claims for parts of the human body	335
D.VIII.2.b.c.	Use claims/purpose-limited product claims for parts of the human body	337
D.VIII.2.b.d.	Human stem cells	337
D.VIII.2.b.d.a.	Introduction	337

D.VIII.2.b.d.b.	Totipotent human stem cells	339
D.VIII.2.b.d.c.	Pluripotent human stem cells	339
D.VIII.2.b.d.d.	Cells obtained by somatic cellular nuclear transfer (SCNT)	339
D.VIII.2.b.d.e.	Stem cells obtained by parthenogenesis	340
D.VIII.2.b.d.f.	Adult stem cells	340
D.VIII.2.b.d.g.	Examples for allowed claims in the field of human stem cells	340
D.VIII.2.c	Summary	342
E.	Patent Infringement	343
E.I.	Introduction	343
E.I.1.	Pre-Suit Considerations	343
E.I.2.	Cross-Border Issues	345
E.I.2.a.	General Principles – limited territorial reach	345
E.I.2.b.	Cross-Border Injunction	346
E.I.2.c.	Torpedo Actions	347
E.II.	Scope of Protection	348
E.II.1.	Claim Construction and Literal Infringement	348
E.II.2.	Equivalent Infringement and Purposive Construction	350
E.II.3.	Specific Claim Categories	355
E.II.3.a.	Product Claims/Compound Claims	355
E.II.3.b.	Composition claims	356
E.II.3.c.	Product-by-Process Claims	357
E.II.3.d.	(Second Medical) Use Claims/“Off label” Use	358
E.II.3.e.	Companion Diagnostic Claims	361
E.II.3.f.	Screening Processes and Reach Through Claims	356
E.II.3.g.	SPCs	365
E.II.3.h.	Plant Variety Rights	366
E.II.4.	Effects of the Patent – Overview	367
E.II.5.	Issues particular to the life sciences	368
E.II.5.a.	Bolar Provision	368
E.II.5.b.	Experimental Use	371
E.II.5.c.	Research Tools	372
E.II.5.d.	EU Biotech Directive	373
E.II.5.e.	Limitations of patent protection available to gene sequences – the Monsanto decision	374
E.III.	Enforcement options	375
E.III.1.	Introduction	375
E.III.2.	Cease and Desist Letter	375
E.III.3.	Criminal Proceedings	375
E.III.4.	Border Seizure	376
E.III.5.	Decision on the merits	377
E.III.5.a.	Bifurcation	377
E.III.5.b.	Discovery	378
E.III.5.c.	Preliminary Relief/Preliminary Injunctions	379
E.IV.	Antitrust	382
E.IV.1.	Introduction	382
E.IV.2.	Sector Inquiry (Pharmaceuticals)	383
E.IV.3.	“Pay-for-delay”/Lundbeck decision	384
E.V.	Unitary Patent and Unified Patent Court	385
E.V.1.	Introduction	385
E.V.2.	Language	385

E.V.3.	Unified Patent Court	386
E.V.3.a.	Introduction	386
E.V.3.b.	Structure	386
E.V.3.c.	Jurisdiction	387
E.V.3.d.	Transitional Period and “opt out”	388
E.V.3.e.	Panels	389
E.V.4.	Sources of Law	389
E.V.5.	Provisional Measures	390
E.V.6.	Parties and their Representation before the UPC	390
E.V.7.	Procedural Issues	391

Annexes

Annex 1	EPC: Articles	393
Annex 2	EPC: Rules – Patentability	400
Annex 3	EPC: Rules – Biological sequences	402
Annex 4	EPC: Rules – Biological deposits	410
Annex 5	EPC: Rules – Form of claims	413
Annex 6	EU-Directive 98/44/EC – Biotech Directive	415
Annex 7	EU Regulations on SPCs (Medicinal products/Plant protection products)	419
Annex 8	EU and international regulations relating to plant varieties	421
Annex 9	Bolar Directives	433
Annex 10	Register of cited decisions	434
Index	443